RIGL Q2 2025 Earnings — Rigel Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

RIGLRigel Pharmaceuticals, Inc.

$541M

Q2 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$102M+176.0% YoY

Gross Profit

$97M95.6% margin

Operating Income

$61M60.1% margin

Net Income

$60M58.6% margin

EPS (Diluted)

$3.28

QoQ Revenue Growth

+90.7%

Cash Flow

Operating Cash Flow

$31M

Free Cash Flow

$31M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$207M

Total Liabilities

$125M

Stockholders' Equity

$82M

Cash & Equivalents

$53M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$102M	$37M	+176.0%
Gross Profit	$97M	$34M	+185.5%
Operating Income	$61M	$447,000	+13569.6%
Net Income	$60M	-$1M	+5887.7%

Revenue Segments

Gross product sales

$80M49%

Product sales, net

$59M36%

Contract revenues from collaborations

$43M26%

Milestone

$3M2%

Discounts and allowances

-$21M-13%